Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (40)

2024

  1. Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis

    Science Advances , Vol. 10, Núm. 42

2023

  1. JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology

    ACS Chemical Neuroscience

  2. JNK3 Overexpression in the Entorhinal Cortex Impacts on the Hippocampus and Induces Cognitive Deficiencies and Tau Misfolding

    ACS Chemical Neuroscience, Vol. 14, Núm. 11, pp. 2074-2088

2022

  1. The Cognitive Improvement and Alleviation of Brain Hypermetabolism Caused by FFAR3 Ablation in Tg2576 Mice Is Persistent under Diet-Induced Obesity

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  2. Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model

    Mechanisms of Ageing and Development, Vol. 204

  3. p27, The Cell Cycle and Alzheimer´s Disease

    International Journal of Molecular Sciences, Vol. 23, Núm. 3

2021

  1. Corticosteroid-binding-globulin (CBG)deficient mice show high pY216-GSK3β and phosphorylated-Tau levels in the hippocampus

    PLoS ONE, Vol. 16, Núm. 2 February

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. GLUT12 Expression in Brain of Mouse Models of Alzheimer’s Disease

    Molecular Neurobiology, Vol. 57, Núm. 2, pp. 798-805

2017

  1. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  2. Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1863, Núm. 4, pp. 991-1001

2016

  1. Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease

    Hippocampus, Vol. 26, Núm. 10, pp. 1303-1312

  2. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 57, pp. 94-105

2015

  1. Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer's disease

    Aging Cell, Vol. 14, Núm. 1, pp. 122-129

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

2014

  1. Decreased rabphilin 3A immunoreactivity in Alzheimer's disease is associated with Aβ burden

    Neurochemistry International, Vol. 64, Núm. 1, pp. 29-36

  2. Expression of the Glucose Transporter GLUT12 in Alzheimer's Disease Patients

    Journal of Alzheimer's Disease, Vol. 42, Núm. 1, pp. 97-101

2013

  1. 5-HT6 receptors and Alzheimer's disease

    Alzheimer's Research and Therapy, Vol. 5, Núm. 2

  2. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients

    Neurobiology of Aging, Vol. 34, Núm. 3, pp. 805-808

  3. Early cognitive stimulation compensates for memory and pathological changes in Tg2576 mice

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1832, Núm. 6, pp. 837-847